Thousand Oaks, California, USA | 17 November 2026
Beren Therapeutics P.B.C. has announced that the U.S. Food and Drug Administration (FDA) has approved LEMBAZ™ (adrabetadex), a new medicine for reducing the risk of death in adults and children living with Niemann-Pick disease type C (NPC) whose neurological symptoms began before six years of age. The approval marks a significant development in the treatment of this rare and progressive genetic disorder, which affects the body’s ability to transport cholesterol and other lipids within cells. According to the company, LEMBAZ is the first FDA-approved medicine demonstrated to improve survival in patients with infantile-onset NPC, addressing an important unmet medical need in rare disease treatment. The medicine is administered through an intrathecal injection, which delivers treatment directly into the fluid surrounding the spinal cord. The FDA approval was granted to Mandos LLC, a subsidiary of Beren Therapeutics, following the regulatory assessment of clinical evidence demonstrating improved overall survival compared with matched external controls. The development also represents an important milestone for cyclodextrin-based pharmaceutical research and the advancement of treatments targeting underlying disease mechanisms rather than managing symptoms alone
FDA Approves LEMBAZ for Infantile-Onset Niemann-Pick Disease
The FDA approved LEMBAZ (adrabetadex) injection for adults and paediatric patients weighing at least 7 kg who have Niemann-Pick disease type C with neurological manifestations beginning before six years of age. NPC is a rare inherited lysosomal storage disorder in which genetic abnormalities affecting NPC1 or NPC2 proteins disrupt the movement of cholesterol and other lipids within cells. As a result, these substances accumulate in cellular compartments, particularly affecting the brain and nervous system. Patients can experience progressive neurological deterioration, including difficulties with movement, coordination, swallowing and other essential functions. Infantile-onset NPC is particularly serious because neurological symptoms appear during early childhood and can lead to substantial disability and premature death. LEMBAZ is designed to address the underlying intracellular cholesterol-trafficking defect associated with the disease through its cyclodextrin-based therapeutic mechanism. The medicine is administered by a trained healthcare professional through an injection into the spinal canal, known as an intrathecal injection, every two weeks. The approval provides a new treatment option for eligible patients, particularly younger individuals with limited therapeutic alternatives.
Clinical Evidence Demonstrates a 55% Reduction in Death Risk
The FDA approval was supported by an overall survival analysis involving 36 patients treated with LEMBAZ across three clinical studies and an Expanded Access Program. Researchers compared their survival outcomes with those of matched external control patients with infantile-onset NPC. The analysis demonstrated a 55% reduction in the risk of death among patients receiving adrabetadex compared with the matched external control group. The median survival time was reported as 8.5 years in the treated group compared with 4.9 years in the control group. The survival benefit was observed regardless of whether patients were also receiving miglustat, another medicine used in NPC treatment. These findings formed the key clinical evidence supporting the FDA’s regulatory decision. Importantly, the survival results were established through a comparison with matched external controls rather than a conventional randomised placebo-controlled trial. The FDA evaluated the available clinical evidence and determined that the comparison provided adequate support for approval. The findings highlight the importance of long-term survival assessments and alternative clinical evidence approaches when developing treatments for rare diseases with limited patient populations. The reported 55% reduction represents a relative reduction in the risk of death, not a 55% increase in survival time
FDA Boxed Warning Highlights Hearing Safety Requirements
Alongside the approval, the FDA has highlighted important safety considerations associated with LEMBAZ treatment. The medicine carries a boxed warning for hearing impairment, including permanent hearing loss. Patients must undergo comprehensive hearing assessments before starting treatment and regularly throughout therapy. These evaluations include audiology tests such as pure-tone audiometry, speech recognition and tympanometry. Healthcare professionals use the assessment results to guide dose adjustments and determine whether treatment can be continued safely. Other reported adverse reactions include balance and coordination difficulties, fatigue, vomiting, back pain, headache, fever, diarrhoea, nausea and cough. The medicine may also cause ataxia, a condition affecting balance and coordination, which can sometimes require hospitalisation. These safety requirements underline the importance of pharmacovigilance, adverse event monitoring and continuous patient assessment following regulatory approval. In addition to receiving FDA approval, Beren Therapeutics was granted a Priority Review Voucher, which can provide regulatory development benefits for future eligible drug applications. The company also announced patient-support initiatives designed to help families identify treatment centres, navigate insurance requirements and access financial assistance. LEMBAZ is expected to become available through commercial treatment sites across the United States in early December 2026
The approval of LEMBAZ represents an important advancement in rare disease pharmaceutical development, clinical research and regulatory science. By targeting the underlying cholesterol-trafficking abnormality and demonstrating improved survival outcomes, adrabetadex introduces a new treatment approach for eligible patients with infantile-onset NPC. The FDA decision also highlights the importance of evaluating long-term clinical outcomes, maintaining patient safety and supporting access to innovative medicines. Continued monitoring of treatment effectiveness and adverse reactions will remain essential as LEMBAZ enters wider clinical use.
Source: Beren Therapeutics press release



